MAP3K6

Across TCGA pan-cancer cohorts, MAP3K6 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAP3K6 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MAP3K6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K6 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

KIRP, BLCA, and COAD are the cancer types where MAP3K6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.144	0.693	<.001	35	view →
BLCA	DFS	Median	All	1.000	0.330	.019	16	view →
COAD	DFS	Median	All	0.375	0.702	.003	8	view →
CESC	OS	Median	III,IV	0.167	0.657	.044	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
ESCA	DFS	Median	All	0.215	0.540	.010	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAP3K6–KIRP (OS)

Open the KIRP breakdown →